Silexion Therapeutics

Company Overview

Snapshot

Founded in November 2008 by Amotz Shemi, PhD, Silexion Therapeutics operates with 11–50 employees. The company has raised $27.65 million across six funding rounds. Silexion Therapeutics went public on NASDAQ in August 2024.

Business overview

Silexion Therapeutics is a developmental stage company focused on creating innovative treatments for pancreatic cancer within the Health Tech & Life Sciences sector. Leveraging RNA interference technology, the company develops RNA-based therapeutics designed to silence specific genes implicated in pancreatic cancer growth and metastasis. Its core product, LODER™, has undergone Phase 2 clinical trials, demonstrating positive efficacy. Silexion is enhancing this first-generation product and developing new formulations to improve clinical efficacy against pancreatic cancer, serving the pharmaceutical and life sciences markets.

Strategic signal

In June 2026, Silexion Therapeutics received approval from Germany's BfArM to initiate a Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer. This approval, following a similar one from the Israeli Ministry of Health in March 2026, signals significant regulatory validation and accelerates the company's clinical development pipeline, indicating strong forward momentum in bringing its next-generation RNA silencing therapy to market.

Company Intelligence Q&A

What was a key regulatory approval for Silexion Therapeutics in 2026?

In June 2026, Silexion Therapeutics received approval from Germany's BfArM to initiate a Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer.

When did Silexion Therapeutics go public?

Silexion Therapeutics went public on NASDAQ in August 2024, following a business combination with Moringa Acquisition Corp.

What was a significant preclinical data announcement for Silexion Therapeutics in 2025?

In March 2025, Silexion Therapeutics reported groundbreaking positive initial data from systemic administration of SIL204 in orthotopic pancreatic cancer models, demonstrating its impact on both primary tumors and metastasis.

What was the outcome of Silexion Therapeutics' public offering in September 2025?

In September 2025, Silexion Therapeutics announced the pricing of a $6.0 million public offering.

What was a notable development regarding SIL204's preclinical studies in May 2025?

In May 2025, Silexion Therapeutics announced groundbreaking preclinical results for SIL204, showing strong efficacy in pancreatic, colorectal, and lung cancers.